open access

Vol 68, No 1 (2017)
Original papers
Published online: 2016-01-22
Submitted: 2015-08-27
Accepted: 2015-11-23
Get Citation

Paraoxonase 1 polymorphisms (L55M and Q192R) as a genetic marker of diabetic nephropathy in youth with type 1 diabetes

Ons Fekih, Sonia Triki, Jihene Rejeb, Fadoua Neffati, Wahiba Douki, Asma Ommezzine, Slaheddine Chouchane, Mohamed Neji Guediche, Ali Bouslama, Mohamed Fadhel Najjar
DOI: 10.5603/EP.a2016.0027
·
Endokrynologia Polska 2017;68(1):35-41.

open access

Vol 68, No 1 (2017)
Original papers
Published online: 2016-01-22
Submitted: 2015-08-27
Accepted: 2015-11-23

Abstract

Introduction: Paraoxonase 1 (PON1) polymorphisms have been largely involved in diabetes complications. The aim of the study is to evaluate the effects of PON1 polymorphisms (L55M and Q192R) on diabetic nephropathy (DN).

Material and methods: The study involved 116 children and adolescents with type 1 diabetes (T1D) and 91 healthy subjects. Albumin excretion rate (AER) was determined by immunoturbidimetry. PON1 activity was measured by a spectrophotometric method, and genotyping of PON1 gene was assessed by multiplex PCR followed by RFLP.

Results: PON1 activity was inversely correlated to AER (r = –0.245, p = 0.008). A significant decrease (p = 0.037) in PON1 activity was shown between patients with nephropathy and those without (162 [57–618] vs. 316 [37–788] IU/L, respectively). The distribution of AER was, for L55M polymorphism MM > LM > LL (p = 0.002), and for Q192R polymorphism QQ > QR > RR (p < 0.001). The opposite distribution was noted for PON 1 activity (p < 0.001). LMQQ and MMQQ haplotypes seem to increase AER (p = 0.004, p = 0.003, respectively) and to reduce PON1 activity (p = 0.011, p = 0.052, respectively) in youths with T1D. However, LLRR haplotype seems to have the opposite effect.

Conclusions: This study demonstrated that PON1 polymorphisms L55M and Q192R seem to be genetic markers involved in the development of DN in T1D. (Endokrynol Pol 2017; 68 (1): 35–41)

Abstract

Introduction: Paraoxonase 1 (PON1) polymorphisms have been largely involved in diabetes complications. The aim of the study is to evaluate the effects of PON1 polymorphisms (L55M and Q192R) on diabetic nephropathy (DN).

Material and methods: The study involved 116 children and adolescents with type 1 diabetes (T1D) and 91 healthy subjects. Albumin excretion rate (AER) was determined by immunoturbidimetry. PON1 activity was measured by a spectrophotometric method, and genotyping of PON1 gene was assessed by multiplex PCR followed by RFLP.

Results: PON1 activity was inversely correlated to AER (r = –0.245, p = 0.008). A significant decrease (p = 0.037) in PON1 activity was shown between patients with nephropathy and those without (162 [57–618] vs. 316 [37–788] IU/L, respectively). The distribution of AER was, for L55M polymorphism MM > LM > LL (p = 0.002), and for Q192R polymorphism QQ > QR > RR (p < 0.001). The opposite distribution was noted for PON 1 activity (p < 0.001). LMQQ and MMQQ haplotypes seem to increase AER (p = 0.004, p = 0.003, respectively) and to reduce PON1 activity (p = 0.011, p = 0.052, respectively) in youths with T1D. However, LLRR haplotype seems to have the opposite effect.

Conclusions: This study demonstrated that PON1 polymorphisms L55M and Q192R seem to be genetic markers involved in the development of DN in T1D. (Endokrynol Pol 2017; 68 (1): 35–41)

Get Citation

Keywords

paraoxonase 1 polymorphisms; type 1 diabetes; diabetic nephropathy; paraoxonase 1 activity

About this article
Title

Paraoxonase 1 polymorphisms (L55M and Q192R) as a genetic marker of diabetic nephropathy in youth with type 1 diabetes

Journal

Endokrynologia Polska

Issue

Vol 68, No 1 (2017)

Pages

35-41

Published online

2016-01-22

DOI

10.5603/EP.a2016.0027

Bibliographic record

Endokrynologia Polska 2017;68(1):35-41.

Keywords

paraoxonase 1 polymorphisms
type 1 diabetes
diabetic nephropathy
paraoxonase 1 activity

Authors

Ons Fekih
Sonia Triki
Jihene Rejeb
Fadoua Neffati
Wahiba Douki
Asma Ommezzine
Slaheddine Chouchane
Mohamed Neji Guediche
Ali Bouslama
Mohamed Fadhel Najjar

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl